tiprankstipranks
Belite Bio, Inc. ADR (BLTE)
NASDAQ:BLTE
US Market
BLTE
Belite Bio, Inc. ADR
RESEARCH TOOLSreports
Want to see BLTE full AI Analyst Report?

Belite Bio, Inc. ADR (BLTE) Stock News & Sentiment

61 Followers
Belite Bio Ramps Toward Tinlarebant Launch
Premium
Company Announcements
Belite Bio Ramps Toward Tinlarebant Launch
6h ago
BLTE
Belite Bio Kicks Off Tinlarebant NDA and Ramps Up Commercial Build-Out on Strong Cash Base
Premium
Company Announcements
Belite Bio Kicks Off Tinlarebant NDA and Ramps Up Commercial Build-Out on Strong Cash Base
19h ago
6K
BLTE
Is BLTE a Buy, Before Earnings?
Premium
Pre-Earnings
Is BLTE a Buy, Before Earnings?
4d ago
BLTE
Buy Initiation on Tinlarebant Developer: First-Mover Stargardt Opportunity Drives DCF-Based $200 Target Amid Key Late-Stage Catalysts and Risks
Premium
Ratings
Buy Initiation on Tinlarebant Developer: First-Mover Stargardt Opportunity Drives DCF-Based $200 Target Amid Key Late-Stage Catalysts and Risks
29d ago
BLTE
Belite Bio Starts FDA Rolling NDA for Tinlarebant in Stargardt Disease
Premium
Company Announcements
Belite Bio Starts FDA Rolling NDA for Tinlarebant in Stargardt Disease
29d ago
6K
BLTE
Belite Bio Faces Higher Compliance Burden as It Becomes a Large Accelerated Filer, Raising Costs and Operational Risk
Premium
Company Announcements
Belite Bio Faces Higher Compliance Burden as It Becomes a Large Accelerated Filer, Raising Costs and Operational Risk
2M ago
BLTE
Belite Bio Posts 2025 Form 20-F Annual Report Online as Late-Stage Retinal Drug Trials Advance
Premium
Company Announcements
Belite Bio Posts 2025 Form 20-F Annual Report Online as Late-Stage Retinal Drug Trials Advance
2M ago
6K
BLTE
More BLTE News >

BLTE News on the Web

Belite Bio Ramps Toward Tinlarebant Launch
TipRanks News
Neutral
Belite Bio Q1 Earnings Call Highlights
MarketBeat
Bullish
Belite Bio (BLTE) Q1 2026 Earnings Transcript
The Motley Fool
Neutral
Belite Bio Kicks Off Tinlarebant NDA and Ramps Up Commercial Build-Out on Strong Cash Base
TipRanks News
Neutral
Belite Bio reports Q1 non-GAAP EPS (34c), consensus (64c)
TipRanks News
Neutral
Belite Bio receives orphan drug status for tinlarebant in Switzerland
TipRanks News
Bullish
Is BLTE a Buy, Before Earnings?
TipRanks News
Bullish
Insider Sell: Nathan Mata Sells Shares of Belite Bio Inc (BLTE)
GuruFocus News
Neutral

News Score - Last 7 Days

Very Positive
BLTE
Sector Average
Media Buzz
This Week8 articles
Weekly Average4.75 articles
News Sentiment
This Week100%
Sector Average76%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is BLTE’s Media Buzz Sentiment?
8 articles about BLTE were published this week. In an average week, 4.75 articles are published.
    What is BLTE’s weekly average amount of articles?
    In an average week, 4.75 articles about BLTE are published.
      What is BLTE’s News Sentiment?
      100% of articles about BLTE were positive this week, compared to its sector average of 76%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        CGENCompugen
        PROKProKidney
        ROIVRoivant Sciences
        Showing the stocks with the most bullish news sentiment over the past week